EGFR and non-small cell lung carcinoma: The first-generation EGFR-TKIs, such as erlotinib and gefitinib, the second-generation, including dacomitinib and afatinib, and the third-generation agent, Osimertinib, are approved as first-line agents for NSCLC harboring EGFR mutations [3,4].